Stock Evaluator: Profound Medical Corp. (PROF)

Profound Medical Corp. PROF

$7.08 0.08 1.14%
August 19, 2026 4:00:00 PM EST November 10, 2021 Volume: 129,849
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Commentary & Analysis


Financial Summary

Share Statistics PROF Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $241.0 $407.7 29%
Shares Out (Mil) 36.4 41.3 40%
Institutional Ownership 94.5% 81.4% 65%
Float (Mil) 35.5 34.9 40%
Beta 0.53 0.88 30%
Avg Daily Volume (000s) 122 412 37%
Price Change
(52-week)
45.2% 64.8% 77%
Growth PROF Industry
Median
Percentile
(All Stocks)
Sales (5yr) 17.1% 11.8% 77%
Net Income (5yr) (14.5%) (6.0%) 26%
EPS (5yr) (2.4%) 10.4% 28
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (47.5%) (16.2%) 8%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 5
Current EPS ($0.228) ($0.863) ($0.588)
Month Ago EPS ($0.243) ($0.844) ($0.752)
# Rev Up 0 1 0
# Rev Down 1 0 0
Three Months Ago EPS ($0.231) ($0.826) ($0.722)
Year/Year Chg (13.0%) (38.7%) (95.0%)
Financials PROF Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $19 $119 13%
Net Income (TTM) (Mil) ($33) ($9) 20%
EPS (TTM) ($0.981) ($0.400) 21%
Operating Cash Flow (TTM) (Mil) ($36) ($3) 11%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $3 $21 21%
Enterprise Value (Q1) (Mil) $225 $427 27%
Valuation PROF Industry
Median
Percentile
(All Stocks)
P/B 4.89 3.06 77%
P/E na 27.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.7 na
Ratios PROF Industry
Median
Percentile
(All Stocks)
Gross Margin 71.8% 58.9% 82%
Net Margin (171.6%) (6.9%) 5%
ROA (58.4%) (12.7%) 10%
ROE (73.5%) (13.1%) 12%
Liabilities to Assets 20.2% 46.0% 13%
F-Score 4 4 34%

Profound Medical Corp. did not pass any screens on 8/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors